LucenceINSIGHT™ Cancer Screening

The regular LucenceINSIGHT™ test covers 12 cancer types: Breast, Gastrointestinal stromal tumor (GIST), Lung (Small cell lung cancer, Non-small cell lung cancer, Lung Neuroendocrine Tumor), Bile Duct, Colorectal, Nasopharyngeal, Liver, Pancreas, Cervical, Prostate.

On the other hand, LucenceINSIGHT™ PLUS covers 50 cancer types: Breast, Gastrointestinal stromal tumor (GIST), Lung (Small cell lung cancer, Non-small cell lung cancer, Lung Neuroendocrine Tumor), Bile Duct, Colorectal, Nasopharyngeal, Liver, Pancreas, Cervical, Prostate, Acute Myeloid Leukemia, Bladder, Endometrium, Eye, Head and Neck, Kidney, Lymphoplasmacytic Lymphoma, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Oropharynx, Skin and Stomach.

In terms of accuracy, Lucence INSIGHT has an 80.9% chance of correctly spotting cancer cases (sensitivity) and a 99% chance of accurately ruling out the disease when it’s not present (specificity).

Reference: https://insight.lucence.com/

LucenceINSIGHT™ serves as a comprehensive tool for early detection across a spectrum of up to 50 cancers, using a straightforward blood test. It identifies cancer-related changes in circulating DNA fragments, known as circulating tumor DNA (ctDNA), released by cancer cells into the bloodstream. Your report will indicate the presence or absence of these “Cancer Signals” as either “Detected” or “Not Detected,” allowing further assessment as needed.

Based on our proprietary next-generation sequencing technology, LucenceINSIGHT™ screens for the signal of cancer with a sensitivity of 80.9% and a specificity of 99%³.

Reference: https://insight.lucence.com/

Early cancer detection is recommended for everyone as a 78% of cancer-related deaths are not addressed by recommended screening methods. Statistics show that early diagnosis can enhance survival rates by up to four times. By identifying cancer at its earliest stages, treatment options are often more effective and less invasive, leading to improved chances of survival and a better quality of life for patients. Furthermore, early detection can empower individuals with the opportunity for proactive management and potentially prevent the disease from progressing to advanced stages.

References:
American Cancer Society. https://www.cancer.org/cancer.html
International Agency for Research on Cancer (IARC). Global Cancer Observatory. https://gco.iarc.fr/. 2020 Data, Accessed Dec 2022.

LucenceINSIGHT™ is recommended in conjunction with existing screening tools for:

• Individuals aged 40 and above without personal history of cancer
• Individuals with elevated risk for cancer (eg, family history of cancer, diet, lifestyle etc)

Note: LucenceINSIGHT™ is not recommended for use in individuals who are pregnant, or have a history of cancer in the past 3 years. 

LucenceINSIGHT™ examines changes in genes, which are like instructions for cell growth and function. Sometimes, alterations (mutations) in genes can make cells grow uncontrollably, leading to cancer.

In contrast, cancer marker tests like CA19-9 or CA-125 look for higher levels of specific proteins produced by cancer cells.

In summary, gene mutations and protein markers play a cause-and-effect role in cancer detection. LucenceINSIGHT™ complements routine cancer screening tools offer additional clarity in early cancer detection.

It’s typically recommended to have screenings annually.

Regular annual screenings play a vital role in detecting cancer at its earliest stages when treatment is often most effective. These screenings allow us to monitor any changes in your health and detect potential signs of cancer early on. We will determine the most suitable screening frequency based on your individual risk factors and medical history.

Results are typically available within 12 to 18 business days. We will contact you once the analysis is complete.